Autores
Catia Marzolini, David Back, Rainer Weber, Hansjakob Furrer, Matthias Cavassini, Alexandra Calmy, Pietro Vernazza, Enos Bernasconi, Saye Khoo, Manuel Battegay, Luigia Elzi, Swiss HIV Cohort Study, M Battegay, E Bernasconi, J Böni, HC Bucher, P Bürgisser, A Calmy, S Cattacin, M Cavassini, R Dubs, M Egger, L Elzi, M Fischer, M Flepp, A Fontana, P Francioli, H Furrer, C Fux, M Gorgievski, H Günthard, HH Hirsch, B Hirschel, I Hösli, Ch Kahlert, L Kaiser, U Karrer, C Kind, Th Klimkait, B Ledergerber, G Martinetti, B Martinez, N Müller, D Nadal, M Opravil, F Paccaud, G Pantaleo, A Rauch, S Regenass, M Rickenbach, C Rudin, P Schmid, D Schultze, J Schüpbach, R Speck, P Taffé, P Tarr, A Telenti, A Trkola, P Vernazza, R Weber, S Yerly
Fecha de publicación
2011/9/1
Revista
Journal of antimicrobial chemotherapy
Volumen
66
Número
9
Páginas
2107-2111
Editor
Oxford University Press
Descripción
Objectives
To compare the use of co-medication, the potential drug–drug interactions (PDDIs) and the effect on antiretroviral therapy (ART) tolerability and efficacy in HIV-infected individuals according to age, ≥50 years or <50 years.
Methods
All ART-treated participants were prospectively included once during a follow-up visit of the Swiss HIV Cohort Study. Information on any current medication was obtained by participant self-report and medical prescription history. The complete treatment was subsequently screened for PDDIs using a customized version of the Liverpool drug interaction database.
Results
Drug prescriptions were analysed for 1497 HIV-infected individuals: 477 age ≥50 and 1020 age <50. Older patients were more likely to receive one or more co-medications compared with younger patients (82% versus 61%; P < 0.001) and thus had …
Artículos de Google Académico
C Marzolini, D Back, R Weber, H Furrer, M Cavassini… - Journal of antimicrobial chemotherapy, 2011
